Citizens JMP lowered the firm’s price target on AMN Healthcare (AMN) to $33 from $34 and keeps an Outperform rating on the shares. AMN’s Q4 revenue comfortably exceeded the firm’s estimate, aided by labor disruption revenue within Nurse and Allied Solutions, the analyst tells investors in a research note. AMN’s Q1 revenue guidance represents the second consecutive quarter where AMN’s outlook has come in ahead of consensus, after guiding below the Street for the prior six quarters, Citizens adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN:
- AMN Healthcare’s Mixed Earnings Call Highlights Challenges and Successes
- AMN Healthcare price target lowered to $26 from $30 at BofA
- AMN Healthcare price target lowered to $40 from $47 at Truist
- Cautious Outlook on AMN Healthcare Services Amid Lower Guidance and Contract Labor Challenges
- AMN Healthcare Reports 2024 Financial Results and Outlook
Questions or Comments about the article? Write to editor@tipranks.com